JCC:饮食摄入模式与IBD患者发生疾病复发风险有关

2021-01-31 MedSci原创 MedSci原创

目前已经有研究表明,饮食与炎症性肠病(IBD)的发作有关。多达一半的IBD患者认为饮食会导致疾病复发。

      目前已经有研究表明,饮食与炎症性肠病(IBD)的发作有关。多达一半的IBD患者认为饮食会导致疾病复发。但是,关于该方向的研究很少,目前仅关注特定的营养素,食品或食物组,而对整体的饮食模式的研究很少。因此,本项研究旨在分析两个地理上不同的荷兰人群的饮食模式与疾病复发发生之间的关联。

 

 

      本项研究共纳入了724名IBD患者(荷兰北部队列纳入486名,荷兰南部队列纳入238名),并随访了两年。在基线时通过半定量食物频率问卷获得习惯性饮食摄入量。研究人员对所有22个食物类别进行了主成分分析(PCA),以识别饮食模式,并进行分类。使用多变量COX比例风险分析了基线处于缓解期的427例IBD患者发生疾病复发的概率。

 

 

      研究结果表明与南部队列相比,北部队列的患者在诊断时较年轻,女性较多,并且总体能量摄入较低(p <0.05)。PCA揭示了三种饮食模式,最明显的模式(占比11.6%)的特征是摄入谷物产品,油,土豆,加工肉,红肉,调味品和糖,蛋糕、糖果等甜品。在427例患者中,有106例(24.8%)在随访期间加重了病情。上述饮食模式与疾病复发的发生有关(HR:1.51,95%CI:1.04-2.18,p = 0.029),而女性也是IBD复发的危险因素(HR:1.63,95%CI 1.04-2.55,p = 0.032)。

 

 

      本项研究表明以油,土豆,加工肉,红肉,调味品和糖,蛋糕、糖果等甜品为主的饮食模式与IBD疾病复发的风险增高有关。

 

 

原始出处:

Vera Peters. Et al. Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients. Journal of Crohn's and Colitis.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798891, encodeId=0fcd1e988917b, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Jan 11 15:41:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905571, encodeId=655b19055e172, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Nov 22 12:41:06 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263631, encodeId=70aa126363187, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Feb 02 11:41:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921763, encodeId=ad52921e6372, content=病从口入!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sun Jan 31 21:46:42 CST 2021, time=2021-01-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798891, encodeId=0fcd1e988917b, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Jan 11 15:41:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905571, encodeId=655b19055e172, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Nov 22 12:41:06 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263631, encodeId=70aa126363187, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Feb 02 11:41:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921763, encodeId=ad52921e6372, content=病从口入!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sun Jan 31 21:46:42 CST 2021, time=2021-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798891, encodeId=0fcd1e988917b, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Jan 11 15:41:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905571, encodeId=655b19055e172, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Nov 22 12:41:06 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263631, encodeId=70aa126363187, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Feb 02 11:41:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921763, encodeId=ad52921e6372, content=病从口入!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sun Jan 31 21:46:42 CST 2021, time=2021-01-31, status=1, ipAttribution=)]
    2021-02-02 bnurmamat
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798891, encodeId=0fcd1e988917b, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Jan 11 15:41:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905571, encodeId=655b19055e172, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Mon Nov 22 12:41:06 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263631, encodeId=70aa126363187, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Feb 02 11:41:06 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921763, encodeId=ad52921e6372, content=病从口入!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sun Jan 31 21:46:42 CST 2021, time=2021-01-31, status=1, ipAttribution=)]
    2021-01-31 用户被禁用

    病从口入!

    0

相关资讯

CELL:炎症性肠病(IBD)的体细胞突变演变

最近,研究人员对46名IBD患者的446个结肠隐窝进行了全基因组测序,并将这些隐窝与其之前发表的41名非IBD对照组的412个隐窝进行了比较,以了解正常结肠的突变情况。

IBD:TGFβ1和IL-6基因中的 CpG甲基化是诊断儿童IBD的生物标志物

找到区分克罗恩病(CD)和溃疡性结肠炎(UC)的诊断标记仍然是个临床难题。本项研究了旨在评估转化生长因子β1(TGFβ1)和白介素6基因启动子的甲基化标记是否具有诊断作用。

GUT:炎症性肠病孕妇药物治疗对后代健康结果的长期影响

患有炎症性肠病的孕妇,在怀孕期间接受抗炎症性肠病药物治疗不会导致后代健康异常

IBD: 炎性肠病患者门静脉血栓形成的发生风险分析

门静脉血栓形成(PVT)是炎症性肠病(IBD)的常见并发症,预后不佳。本项研究旨在试图更好地描述IBD患者出现PVT的危险因素,并比较不同的治疗方法及对于IBD相关PVT的预后。

AP&T: 血清甲状腺素T3与甲状腺素T4(T3 / T4)的比值可预测老年IBD患者对生物疗法的治疗效果

老年炎症性肠病(IBDs)的发病率正在逐渐增加,并且老年对于目前的药物治疗方案有着与年轻人不一样的反应,因此,需要另外的生物标记物来优化其治疗方法。

Gastroenterology:激素治疗增加炎症性肠病患者新冠肺炎感染后重症风险

高龄及接受系统性激素治疗的炎症性肠病患者发展为重症新冠肺炎患者的风险较高,使用肿瘤坏死因子拮抗剂治疗则较为安全。